GC and its GC LabCell subsidiary both contributed to a round that will help advance the cancer immunotherapy developer's NK cell drug pipeline.
US-based cancer therapy developer Artiva Biotherapeutics completed a $120m series B round on Friday featuring drug producer GC LabCell and its parent company, GC.
The round was led by venture capital firm Venrock’s Healthcare Capital Partners while 5AM Ventures, RA Capital Management and VenBio Partners all participated as existing backers.
New investors including Acuta Capital Partners, Cormorant Asset Management, EcoR1 Capital, Franklin Templeton, Janus Henderson Investors, Logos Capital, RTW Investments, Surveyor Capital and Wellington Management Company filled out the round.
…
